Refine
Year of publication
Document Type
- Article (73) (remove)
Has Fulltext
- yes (73)
Is part of the Bibliography
- no (73)
Keywords
- COVID-19 (4)
- SARS-CoV-2 (3)
- risk factors (3)
- ACLF (2)
- Biomarkers (2)
- Immunology (2)
- Non-small cell lung cancer (2)
- Portal hypertension (2)
- acute myeloid leukemia (2)
- acute-on-chronic liver failure (2)
- cirrhosis (2)
- inflammation (2)
- portal hypertension (2)
- 32D progenitor cells (1)
- 3years (1)
- ABCB1 (1)
- ABCC1 (1)
- ADGRE1 (1)
- ALK-rearranged NSCLC (1)
- Acute Myeloid Leukemia (AML) (1)
- Acute kidney injury (1)
- Advanced stage (1)
- Alternative oxidase (1)
- Angiogenesis (1)
- Angiography (1)
- Ankylosierende Spondylitis (1)
- Ankylosing spondylitis (1)
- Axial spondyloarthritis (1)
- Axiale Spondyloarthritis (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- BRVO (1)
- Blood (1)
- Blood loss (1)
- Blood plasma (1)
- Brain tumor (1)
- CAKUT (1)
- CBA (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- COPD (1)
- COVID (1)
- CV9202 (1)
- CVD biomarker (1)
- Cancer (1)
- Cardiology (1)
- Care gaps (1)
- Cirrhosis (1)
- Clinical trial (1)
- Cohort studies (1)
- Colloids (1)
- Complicated stage (1)
- DME (1)
- Devic disease (1)
- Devic syndrome (1)
- Diabetes (1)
- Drug resistance (1)
- Drug targets (1)
- EMR1 (1)
- EWSR1 (1)
- Emphysema (1)
- Everolimus (1)
- Extended donor criteria (1)
- F4/80 (1)
- FOXO3a (1)
- G3BP (1)
- Gene fusion (1)
- Genetic testing (1)
- Genetics (1)
- Germany (1)
- Graft function (1)
- Graft survival (1)
- HES (1)
- Haematocrit (1)
- Hashimoto’s thyroiditis (1)
- Health care (1)
- Health information (1)
- Health-seeking behaviour (1)
- Heat shock protein 27 (1)
- Helpline (1)
- Hydroxyethyl starch (1)
- Hypofractionated radiotherapy (1)
- IL-6 (1)
- ILUVIEN (1)
- Immunogenetics (1)
- Immunomonitoring (1)
- JAK2V617F (1)
- K3EDTA plasma sampling (1)
- Kidney transplantation (1)
- LEOSS (1)
- Lipidomics (1)
- Liver cirrhosis (1)
- Liver transplantation (1)
- Ltbp4 (1)
- MCP (1)
- MN1 (1)
- MR-proADM (1)
- Machine learning (1)
- Marginal grafts (1)
- Mean erythrocyte volume (1)
- Medication Appropriateness Index (1)
- Metabolic models (1)
- Metabolic vulnerabilities (1)
- Metabolomics (1)
- Mitochondria (1)
- Mitochondrial disease (1)
- Molecular diagnostic testing (1)
- Molecular medicine (1)
- Mortality (1)
- NAFL (1)
- NAFLD (1)
- NASH (1)
- NMO-IgG (1)
- Nephrons (1)
- Neuroepithelial (1)
- Neuromyelitis optica (1)
- Neurooncology (1)
- Nrf2 (1)
- Number of platelets (1)
- Oncology (1)
- Organ rinse (1)
- Organ shortage (1)
- PATZ1 (1)
- PTDM (1)
- Pdgfrβ (1)
- Pediatric (1)
- Periodontitis grades B and C (1)
- Polo-like kinase 3 (1)
- Portal veins (1)
- Post-transplant (1)
- Pre-analytics (1)
- Predictive model (1)
- Primary prophylaxis (1)
- Proteins (1)
- Psychiatric disorders (1)
- Quality of care (1)
- Quality standards (1)
- Qualitätsstandards (1)
- ROS (1)
- Radical nephrectomy (1)
- Rare diseases (1)
- Registries (1)
- Renal cancer (1)
- Renal system (1)
- Respiratory chain (1)
- Retro-IDEAL (1)
- Rho GTPases (1)
- SD-OCT (1)
- SLC20A1 (1)
- SOFA (1)
- SPSS (1)
- Sampling protocol (1)
- Sepsis (1)
- Septic shock (1)
- Spontaneous bacterial peritonitis (1)
- Steroid (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival analysis (1)
- TGR(mREN2)27 (1)
- TOR inhibitor (1)
- TP53 mutation status (1)
- Tacrolimus (1)
- Telemedicine (1)
- Tgfβ (1)
- Trauma (1)
- VEGF (1)
- Versorgungslücken (1)
- Versorgungsqualität (1)
- Volume therapy (1)
- Western diet (1)
- White blood cells (1)
- YM155 (1)
- accident (1)
- acute decompensation (1)
- acute-on-chronic liver failure (ACLF) (1)
- adhesion (1)
- advanced care planning (1)
- aftercare structures (1)
- aging (1)
- anal carcinoma (1)
- anticonvulsants (1)
- aquaporin-4 (AQP4) antibody (1)
- bladder exstrophy-epispadias complex (1)
- bleeding (1)
- cancer (1)
- caspase-8 (1)
- cerebrospinal fluid (1)
- chemoradiotherapy (1)
- chronic kidney disease (1)
- chronic myeloid leukemia (1)
- clinical features (1)
- cloacal malformation (1)
- comorbidities (1)
- computed tomography (1)
- computer-assisted drug therapy (1)
- consensus (1)
- critically ill patients (1)
- cytarabine dose (1)
- day clinic (1)
- decompensated liver cirrhosis (1)
- differentiated thyroid carcinoma (1)
- drug resistance (1)
- dysbiosis (1)
- elderly (1)
- epidemiology (1)
- epilepsy (1)
- epileptic encephalopathies (1)
- essential thrombocythemia (ET) (1)
- functional genetics (1)
- glycobiology (1)
- glycoconjugate (1)
- health information exchange (1)
- hepatic encephalopathy (1)
- homing (1)
- hospital admission (1)
- immunity (1)
- infectious disease (1)
- injury (1)
- kidney formation (1)
- lasso regression (1)
- lethal toxin (1)
- levetiracetam (1)
- liver (1)
- liver fibrosis (1)
- liver transplantation (1)
- liver transplantation center (1)
- local control (1)
- lockdown (1)
- long-term outcome (1)
- longitudinally extensive transverse myelitis (1)
- loss-of-function (1)
- mRNA active cancer immunotherapy (1)
- macrophage (1)
- magnetic resonance imaging (1)
- male (1)
- mechanical ventilation (1)
- medication reconciliation (1)
- metabolic reprogramming (1)
- metabolic syndromes (1)
- microbiome (1)
- microdosing (1)
- migration (1)
- molecular modeling (1)
- monocyte chemotactic protein 1 (MCP-1) (1)
- mortality (1)
- multimodal complex treatment (1)
- multimorbidity (1)
- multiple chronic conditions (1)
- myeloproliferative neoplasms (MPN) (1)
- networks (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurological manifestations (1)
- neutralizing antibodies (1)
- nomogram (1)
- pediatric intensive care (1)
- peri-implantitis (1)
- polycythemia vera (PV) (1)
- polypharmacy (1)
- portosystemic shunt (1)
- post-liver transplantation management (1)
- primary myelofibrosis (PMF) (1)
- proteomics (1)
- pulmonary failure (1)
- qualitative research (1)
- quality control (1)
- rare diseases (1)
- recurrent optic neuritis (1)
- renal dysfunction (1)
- respiratory failure (1)
- retrovirus (1)
- risk factor progression (1)
- risk stratification (1)
- seizure (1)
- sequential ALK-inhibitor therapy (1)
- sialic acid (1)
- sirtuin1 (1)
- spike protein (1)
- spontaneous portosystemic shunt (1)
- survival (1)
- survivin (1)
- thromboembolism (1)
- thrombosis (1)
- toxin B (1)
- transjugular intrahepatic portosystemic shunt (TIPS) (1)
- trauma (1)
- tyrosine kinase inhibitors. (1)
- urinary tract development (1)
- variants of concern (1)
- vitamin D (1)
- vitamin D receptor (1)
- vitreous samples (1)
- zebrafish development (1)
Institute
- Medizin (73) (remove)
Peri-implantitis: summary and consensus statements of group 3. The 6th EAO Consensus Conference 2021
(2021)
Objective: To evaluate the influence of implant and prosthetic components on peri-implant tissue health. A further aim was to evaluate peri-implant soft-tissue changes following surgical peri-implantitis treatment. Materials and methods: Group discussions based on two systematic reviews (SR) and one critical review (CR) addressed (i) the influence of implant material and surface characteristics on the incidence and progression of peri-implantitis, (ii) implant and restorative design elements and the associated risk for peri-implant diseases, and (iii) peri-implant soft-tissue level changes and patient-reported outcomes following peri-implantitis treatment. Consensus statements, clinical recommendations, and implications for future research were discussed within the group and approved during plenary sessions. Results: Data from preclinical in vivo studies demonstrated significantly greater radiographic bone loss and increased area of inflammatory infiltrate at modified compared to non-modified surface implants. Limited clinical data did not show differences between modified and non-modified implant surfaces in incidence or progression of peri-implantitis (SR). There is some evidence that restricted accessibility for oral hygiene and an emergence angle of >30 combined with a convex emergence profile of the abutment/prosthesis are associated with an increased risk for peri-implantitis (CR). Reconstructive therapy for peri-implantitis resulted in significantly less soft-tissue recession, when compared with access flap. Implantoplasty or the adjunctive use of a barrier membrane had no influence on the extent of peri-implant mucosal recession following peri-implantitis treatment (SR).
Objective: Liver stiffness measurement (LSM) is a tool used to screen for significant fibrosis and portal hypertension. The aim of this retrospective multicentre study was to develop an easy tool using LSM for clinical outcomes in advanced chronic liver disease (ACLD) patients.
Design: This international multicentre cohort study included a derivation ACLD patient cohort with valid two-dimensional shear wave elastography (2D-SWE) results. Clinical and laboratory parameters at baseline and during follow-up were recorded. LSM by transient elastography (TE) was also recorded if available. The primary outcome was overall mortality. The secondary outcome was the development of first/further decompensation.
Results: After screening 2148 patients (16 centres), 1827 patients (55 years, 62.4% men) were included in the 2D-SWE cohort, with median liver SWE (L-SWE) 11.8 kPa and a model for end stage liver disease (MELD) score of 8. Combination of MELD score and L-SWE predict independently of mortality (AUC 0.8). L-SWE cut-off at ≥20 kPa combined with MELD ≥10 could stratify the risk of mortality and first/further decompensation in ACLD patients. The 2-year mortality and decompensation rates were 36.9% and 61.8%, respectively, in the 305 (18.3%) high-risk patients (with L-SWE ≥20 kPa and MELD ≥10), while in the 944 (56.6%) low-risk patients, these were 1.1% and 3.5%, respectively. Importantly, this M10LS20 algorithm was validated by TE-based LSM and in an additional cohort of 119 patients with valid point shear SWE-LSM.
Conclusion: The M10LS20 algorithm allows risk stratification of patients with ACLD. Patients with L-SWE ≥20 kPa and MELD ≥10 should be followed closely and receive intensified care, while patients with low risk may be managed at longer intervals.
TRIANNI mice carry an entire set of human immunoglobulin V region gene segments and are a powerful tool to rapidly isolate human monoclonal antibodies. After immunizing these mice with DNA encoding the spike protein of SARS-CoV-2 and boosting with spike protein, we identified 29 hybridoma antibodies that reacted with the SARS-CoV-2 spike protein. Nine antibodies neutralize SARS-CoV-2 infection at IC50 values in the subnanomolar range. ELISA-binding studies and DNA sequence analyses revealed one cluster of three clonally related neutralizing antibodies that target the receptor-binding domain and compete with the cellular receptor hACE2. A second cluster of six clonally related neutralizing antibodies bind to the N-terminal domain of the spike protein without competing with the binding of hACE2 or cluster 1 antibodies. SARS-CoV-2 mutants selected for resistance to an antibody from one cluster are still neutralized by an antibody from the other cluster. Antibodies from both clusters markedly reduced viral spread in mice transgenic for human ACE2 and protected the animals from SARS-CoV-2-induced weight loss. The two clusters of potent noncompeting SARS-CoV-2 neutralizing antibodies provide potential candidates for therapy and prophylaxis of COVID-19. The study further supports transgenic animals with a human immunoglobulin gene repertoire as a powerful platform in pandemic preparedness initiatives.